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In 1952 cortisone therapy was initiated in two patients with far advanced
prostatic carcinoma.2 As part of the study of those patients, determinations
were made of urinary 17-ketosteroid excretion before and during therapy
with cortisone. Rather large increases in excretion of 17-ketosteroids were
noted during the administration of high doses of cortisone in both patients.
This unexpected finding led to an investigation of the effect of cortisone on
17-ketosteroid excretion, the preliminary results of which are now being
reported.
The following somewhat arbitrary procedure was adopted for the initial
phase of this study. Three 24-hour urine samples were collected for base-
line 17-ketosteroid determination. Cortisone acetate was then administered
orally for three days in four doses of 75 mg. each, a total of 300 mg. per
day; three 24-hour urine specimens were collected during this "cortisone
period." Whenever possible, the experiment was completed during six con-
secutive days, during which no major change in the patient's course or
treatment took place. In a few instances this was not possible, and the base-
line and cortisone periods were not similar in all respects. Occasionally,
three specimens could not be collected for each period, and base-line or
cortisone figures are based on one or two determinations. With one
exception, all patients were hospitalized during the study.
The 17-ketosteroid determinations were performed in triplicate by a
modification of the method of Masuda and Thuline,' using the Zimmerman
reaction. Determinations on all six urine specimens were usually performed
on the same day, under identical conditions, by a technician who did not
know the patient's diagnosis.
Studies have been completed on eighteen patients. Six of them had car-
cinoma of the prostate. Different stages of this disease were represented;
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for example, in one case the disease was sufficiently localized to war-
rant treatment by radical prostatectomy; two presented extensive bone
metastases, pulmonary involvement, and anemia. Eight patients were "con-
trols" without neoplastic disease. Three of these were essentially well indi-
viduals undergoing rehabilitation from paralytic poliomyelitis. The others
were chronically ill patients. Four patients had inoperable malignant disease
not known to be primary in the prostate. One of the "control" patients was
a young woman; all other patients were men. Table 1 summarizes the
major features of these eighteen case histories.
RESULTS
The 17-ketosteroid determinations on this group of eighteen patients are
presented in Table 2. The base-line values fell within the usual range and
varied as would be expected with sex and age, except that several of the
patients with carcinoma of the prostate excreted somewhat larger amounts
than usual for elderly men. In general, there was relatively little variation
among the three base-line urine specimens from any one patient.
There was considerable variation in 17-ketosteroid excretion during the
first day cortisone was administered. In some cases it was close to the base-
line figure; in others it was in the same range as the excretion during the
second and third day. Because of the variability, this figure was not used in
making comparisons between different groups of patients.
During the second and third cortisone days the patients without malig-
nant neoplasms excreted somewhat larger amounts of 17-ketosteroids than
during the base-line period. The average increment over the base line for
this group of eight patients was 4.3 mg. per 24 hours. Individual values
ranged from a decrement of 2.3 mg. to an increment of 11.7 mg. In one
patient the excretion on the third day exceeded that on the second day by
5 mg. or more; in another, the reverse was true. The averages for the
second and third days were not significantly different.
Considerable increase in 17-ketosteroid excretion during the second and
third days of cortisone administration was noted in all six patients with
carcinoma of the prostate. The average increment over the base-line for this
group was 21.8 mg. per 24 hours. This was five times the figure for the
"control" group. Individual increments ranged from 9.1 mg. to 34.7 mg.
The smallest average increment for any patient was 17.1 mg. In three
patients the excretion on the third day exceeded that on the second by
10 mg. or more. In no patient did the second day's excretion significantly
exceed the third. The average for the third day was appreciably higher than
the second. These figures suggest that, in contrast to the patients with non-
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TABLE 1. PATIENTS. DIAGNOSIS AND CLINICAL DATA
Case Sex Age
1 F 22 Paralytic poliomyelitis two months before test. Undergoing physio-
therapy and retraining. Urinary tract infection.
2 M 24 Degenerative cerebellar disease of long duration. Undergoing
physiotherapy and retraining.
3 M 38 Paralytic poliomyelitis two years before test. Undergoing physio-
therapy and retraining. Flail legs, arthritis of hips and spine,
palpable liver and spleen, chronic sinusitis.
4 M 80 Benign overgrowth of prostate, symptomatic. Incomplete emptying
of bladder, urinary tract infection, severe arteriosclerosis, senility.
5 M 61 Multiple cerebral thromboses. Semicomatose. Suprapubic cystos-
tomy. Urinary tract infection, malnutrition, decubiti, fever. (On
Danger List.)
6 M 73 Anemia, hypo-albuminemia, weight loss, joint pain. Benign over-
growth of prostate, bilateral hydronephrosis, degenerative arthritis
of hip, slight fever. Inlying catheter.
7 M 29 Paralytic poliomyelitis one year before test. Undergoing physio-
therapy and retraining.
8 M 43 Multiple sclerosis of long duration, with mental deterioration. Ele-
vated spinal fluid protein.
9 M 72 Carcinoma of the prostate. Orchiectomized; on stilbestrol. Local
extension of tumor.
10 M 66 Carcinoma of the prostate. Orchiectomized; on stilbestrol. Local
extension of tumor, multiple osteoblastic bone metastases, pul-
monary infiltration, anemia. Elevated acid and alkaline phosphatase.
11 M 74 Carcinoma of the prostate. Radical prostatectomy five days before
test. Arthritis.
12 M 74 Carcinoma of the prostate. Orchiectomized; on stilbestrol. Multiple
osteoblastic bone metastases, pulmonary infiltration, anemia. Nor-
mal phosphatases.
13 M 76 Carcinoma of the prostate. Orchiectomized; on stilbestrol. Multi-
ple osteoblastic bone metastases.
14 M 59 Carcinoma of the prostate. Orchiectomized; on stilbestrol. Local
extension of tumor, urinary symptoms, edema of one leg.
15 M 24 Hodgkin's disease. Fever, anemia, pleural effusions, bone lesions.
16 M 74 Metastatic carcinoma of bone, primary site unknown. Benign over-
growth of prostate. Elevated alkaline phosphatase.
17 M 53 Epidermoid carcinoma of bladder. Invasion of prostate, ureteral
obstruction. Phosphatases normal.
18 M 68 Carcinoma of the head of the pancreas, lymph node metastases.
Laparotomy and cholecystojejunostomy seven days before test.
Obstructive jaundice, two months.
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malignant disease, steroid excretion was still rising on the third cortisone
day among the patients with prostatic cancer.
Three of the patients with other neoplasms reacted like the group with
prostatic cancer. The fourth, Case 18, reacted like the controls. It may be
significant that this patient had impairment of liver function.
DISCUSSION
The difference between the responses of patients without malignant
disease and those with cancer of the prostate is quite striking. As is shown
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FIG. 1. Increments in 17-ketosteroid excretion during the second and third cortisone
days. The columns represent the range of values for the respective groups of patients;
each horizontal line across a column represents the mean value for that group.
in Figure 1, there is no overlap between the two groups on either the second
or the third cortisone day, and the mean increment in 17-ketosteroid excre-
tion in the latter group is more than five times that of the former. It is
possible that the difference would have been even greater had the experi-
mental period been longer. The data suggest that 17-ketosteroid excretion
was still rising on the third cortisone day in some patients with prostatic
carcinoma; this did not seem to be true of the non-malignant group.
There are relatively few data in the literature on 17-ketosteroid excretion
by patients receiving doses of cortisone comparable to those used in this
study. Burstein, Savard, and Dorfman' studied the urinary steroids ex-
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creted by an essentially healthy man who ingested 2,500 mg. of cortisone
over a five-day period. Calculations from their data indicate that there was
no rise in 17-ketosteroids during this period. Sandberg, et al." noted a small
increment in the 17-ketosteroid excretion of a 42-year-old man with rheu-
matoid arthritis during a course of therapy with 300 mg. of cortisone daily.
Maddock, Chase, and Nelson' determined 17-ketosteroid excretion of four
male patients with rheumatoid arthritis who were receiving 500-800 mg. of
cortisone daily by intramuscular injection. They reported increases of 3 to
13 mg. per 24 hours over base-line excretion. The findings in these three
studies are consistent with our "non-malignant" response.
Valk and Owens7 and Harrison, Thorn, and Jenkins' indicated that
administration of large doses of cortisone to patients with carcinoma of the
prostate resulted in increased 17-ketosteroid excretion. Figures pertinent to
our study are given for only one patient-Case 3 of the latter report. This
patient's 17-ketosteroid excretion rose from 6 to 47 mg. per 24 hours after
five days of administration of hydrocortisone at a dose of 300 mg. per day.
This is consistent with our "positive" response.
Discussion of the mechanisms involved in the production of these differ-
ences in ketosteroid excretion must await the accumulation of additional
data. Several conclusions may be drawn from this preliminary study. These
differences do not reflect the over-all clinical status or nutritional balance of
the patients. Two of the patients with prostatic carcinoma were in excellent
condition except for their local disease. The sickest patient in this series, on
the other hand, was Case 5, a "control." Non-malignant disease of the
prostate did not produce a "positive" response. There was no correlation
with acid phosphatase, alkaline phosphatase, or the presence or absence of
demonstrable bone involvement.
The sensitivity of this response is not known. None of the patients in this
series could be said to have "early" or "questionable" cancer, although two
had disease of relatively limited extent. Of considerable interest is the ques-
tion whether the phenomenon under study is especially related to prostatic
malignancy, or whether it is common to many forms of cancer. Studies now
under way should shed light on this and other questions, which largely
determine the usefulness of a "cancer test."
The cortisone "test" was ordinarily performed only upon patients whose
diagnoses were known. An interesting exception was Case 16. This 74-
year-old man was admitted in a semicomatose state, with fever, stiff neck,
and a type III pneumococcal bacteremia. He improved gradually on inten-
sive antibiotic therapy. X-ray examinations revealed increased densities in
the ribs, spine, pelvis, and femora. Clinical opinion was divided, with some
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observers favoring the diagnosis of metastatic carcinoma of bone, and
others, Paget's disease. Repeated careful examinations revealed no primary
site of carcinoma. Two bone marrow aspirations and a needle biopsy of the
prostate were negative. However, the 17-ketosteroid excretion rose sharply
during cortisone administration. Largely on the strength of this finding,
surgical biopsy of a rib was performed, and metastatic carcinoma was
demonstrated. The primary site has not yet been discovered.
SUMMARY
The effect of large doses of cortisone on 17-ketosteroid excretion
was studied in patients with and without malignant neoplastic disease.
Eight patients without cancer showed little or no increase in uri-
nary 17-ketosteroids while receiving 300 mg. of cortisone acetate per day.
Six patients with carcinoma of the prostate showed a marked increase in
17-ketosteroid excretion under similar conditions of cortisone administra-
tion. There was no overlap between these two groups. Three of four
patients with other malignancies showed a response similar to that of the
patients with prostatic cancer. The possibility that this phenomenon may
have some clinical usefulness as a "cancer test" is being investigated.
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